BioSpace News Archive

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Sanofi and Swedish Orphan Biovitrum AB announced positive topline results from the pivotal XTEND-1 Phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa in previously treated patients ≥12 years of age with severe hemophilia A.

March 9, 2022
·
9 min read
Sequana Medical to Present at BioCapital Europe and Oppenheimer’s Annual Healthcare Conference

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that Ian Crosbie, Chief Executive Officer, will present at the following upcoming investor conferences in March 2022.

March 9, 2022
·
4 min read
Spexis to Present Strategy Update and Full-Year 2021 Financial Results on March 24, 2022

Spexis AG announced that it will publish its full-year financial results for 2021 on March 24 at 7.30am CET.

March 9, 2022
·
2 min read
Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022

Transgene and BioInvent International AB jointly announce that an abstract reporting preclinical studies of BT-001, a novel oncolytic virus, has been selected for a poster presentation at the American Association for Cancer Research Annual Meeting 2022.

March 9, 2022
·
7 min read
Drug Development

Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting

Nordic Nanovector ASA announces that an E-poster regarding Alpha37, entitled “Targeted alpha therapy with 212Pb-NNV003 in treatment of NHL”, will be presented at the 2022 American Association of Cancer Research Annual Meeting held 8-13 April in New Orleans, USA.

March 9, 2022
·
4 min read
Drug Development

iOnctura to Present Preclinical Data on its Clinical Stage Autotaxin Inhibitor, IOA-289, at AACR

iOnctura SA will present preclinical data on its next-generation autotaxin inhibitor, IOA-289, at the annual meeting of the American Association for Cancer Research taking place on April 8-13, 2022 in New Orleans, Louisiana.

March 9, 2022
·
2 min read
Drug Development

Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer will be presenting a poster with new and promising preliminary Phase I data on TG4050, its individualized neoantigen cancer vaccine, at the AACR Annual Meeting 2022.

March 9, 2022
·
7 min read
Business

Tataa Biocenter is partnering with Olink and Illumina to offer high performance proteomics with unprecedented throughput

Tataa Biocenter AB, a leading European provider of molecular analysis services with ISO 17025 accreditation, is launching Olink® EXPLORE 3072 proteome profiling service.

March 9, 2022
·
3 min read
Genetown

Ultivue Announces Co-Marketing Agreement with Aignostics for Unique Spatial AI-Powered Imaging Solutions for Translational Medicine

Ultivue, Inc. and Aignostics GmbH announced a partnership to collaborate on the co-development of AI-powered spatial multiplexed immunophenotype solutions for translational research groups and Biopharma.

March 9, 2022
·
3 min read
Business

Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview

Protara Therapeutics, Inc. today announced financial results for the fourth quarter and year ended December 31, 2021.

March 9, 2022
·
12 min read